Lakefront swings to €16.6M H1 profit, holds ~€2B year-end cash target
LKFT is trading near its 52-week low of $25.68 (11% above the low) on elevated volume (2.6× avg).
Summary
Lakefront Biotherapeutics posted a €16.6M net profit for H1 2026, guided to ~€2B in year-end cash, and provided clinical updates including Fast Track designation for gamgertamig and a Phase 2 miss for GLPG3667.
Key Events · Earnings and Guidance · LKFT
-
H1 2026 Net Profit of €16.6M
Driven by an 80% drop in R&D expenses to €56.5 million and a €97.1 million fair value gain on financial investments and currency, Lakefront swung to a net profit of €16.6 million from a €259.1 million loss in H1 2025.
-
Year-End Cash Guidance Maintained at ~€2B
Year-end 2026 cash and financial investments are expected to land between €1.975 billion and €2.050 billion, a range that now includes the €50 million share repurchase program. At least €1.6 billion is forecast to remain after funding the portfolio to first gamgertamig approval.
-
Gamgertamig Receives FDA Fast Track and Orphan Drug Designation
The lead asset gamgertamig, a BCMAxCD3 T-cell engager, was granted Fast Track and Orphan Drug Designation for AIHA and ITP. Phase 1b studies are enrolling, and registrational studies are expected in 2027.
-
GLPG3667 Phase 2 Results Mixed; Strategic Options Under Review
While the GALARISSO study in dermatomyositis showed sustained efficacy, the GALACELA study in lupus missed its primary endpoint. Lakefront is evaluating all strategic options for the program.
Analysis · LKFT · Life Sciences
A sharp reduction in R&D spending and a €97.1 million fair value gain propelled Lakefront Biotherapeutics to a net profit of €16.6 million for the first half of 2026, reversing a €259.1 million loss in the prior-year period. The company closed June with €2.24 billion in cash and investments and guided to a year-end balance of €1.975–€2.050 billion — a range that now incorporates the €50 million share buyback. Management also signaled that at least €1.6 billion should remain after funding the portfolio through the first approval of lead asset gamgertamig, highlighting a fortress balance sheet. On the pipeline front, gamgertamig secured FDA Fast Track and Orphan Drug Designation, Phase 1b trials are enrolling, and registrational studies are expected in 2027. Meanwhile, the TYK2 inhibitor GLPG3667 missed its primary endpoint in lupus, and the company is evaluating strategic options. The results confirm Lakefront's transformation into a well-capitalized, immunology-focused biotech with a clear path forward.
At the time of this filing, LKFT was trading at $28.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $25.68 to $37.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.